These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 27072700)

  • 1. Paralog Specific Hsp90 Inhibitors - A Brief History and a Bright Future.
    Gewirth DT
    Curr Top Med Chem; 2016; 16(25):2779-91. PubMed ID: 27072700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2.
    Patel PD; Yan P; Seidler PM; Patel HJ; Sun W; Yang C; Que NS; Taldone T; Finotti P; Stephani RA; Gewirth DT; Chiosis G
    Nat Chem Biol; 2013 Nov; 9(11):677-84. PubMed ID: 23995768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structures of Hsp90α and Hsp90β bound to a purine-scaffold inhibitor reveal an exploitable residue for drug selectivity.
    Huck JD; Que NLS; Sharma S; Taldone T; Chiosis G; Gewirth DT
    Proteins; 2019 Oct; 87(10):869-877. PubMed ID: 31141217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5'-N-ethylcarboxamidoadenosine is not a paralog-specific Hsp90 inhibitor.
    Liu S; Street TO
    Protein Sci; 2016 Dec; 25(12):2209-2215. PubMed ID: 27667530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gambogic acid identifies an isoform-specific druggable pocket in the middle domain of Hsp90β.
    Yim KH; Prince TL; Qu S; Bai F; Jennings PA; Onuchic JN; Theodorakis EA; Neckers L
    Proc Natl Acad Sci U S A; 2016 Aug; 113(33):E4801-9. PubMed ID: 27466407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different poses for ligand and chaperone in inhibitor-bound Hsp90 and GRP94: implications for paralog-specific drug design.
    Immormino RM; Metzger LE; Reardon PN; Dollins DE; Blagg BS; Gewirth DT
    J Mol Biol; 2009 May; 388(5):1033-42. PubMed ID: 19361515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NECA derivatives exploit the paralog-specific properties of the site 3 side pocket of Grp94, the endoplasmic reticulum Hsp90.
    Huck JD; Que NLS; Immormino RM; Shrestha L; Taldone T; Chiosis G; Gewirth DT
    J Biol Chem; 2019 Nov; 294(44):16010-16019. PubMed ID: 31501246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substitution of only two residues of human Hsp90alpha causes impeded dimerization of Hsp90beta.
    Kobayakawa T; Yamada S; Mizuno A; Nemoto TK
    Cell Stress Chaperones; 2008; 13(1):97-104. PubMed ID: 18347946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Redefining the Phenotype of Heat Shock Protein 90 (Hsp90) Inhibitors.
    Wang Y; Koay YC; McAlpine SR
    Chemistry; 2017 Feb; 23(9):2010-2013. PubMed ID: 27862436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expressed as the sole Hsp90 of yeast, the alpha and beta isoforms of human Hsp90 differ with regard to their capacities for activation of certain client proteins, whereas only Hsp90beta generates sensitivity to the Hsp90 inhibitor radicicol.
    Millson SH; Truman AW; Rácz A; Hu B; Panaretou B; Nuttall J; Mollapour M; Söti C; Piper PW
    FEBS J; 2007 Sep; 274(17):4453-63. PubMed ID: 17681020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Organelle-specific Hsp90 inhibitors.
    Seo YH
    Arch Pharm Res; 2015 Sep; 38(9):1582-90. PubMed ID: 26195286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and pharmacological evaluation of ALK and Hsp90 dual inhibitors bearing resorcinol and 2,4-diaminopyrimidine motifs.
    Geng K; Liu H; Song Z; Zhang C; Zhang M; Yang H; Cao J; Geng M; Shen A; Zhang A
    Eur J Med Chem; 2018 May; 152():76-86. PubMed ID: 29698859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A simple yeast-based system for analyzing inhibitor resistance in the human cancer drug targets Hsp90alpha/beta.
    Millson SH; Prodromou C; Piper PW
    Biochem Pharmacol; 2010 Jun; 79(11):1581-8. PubMed ID: 20138026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and biological evaluation of a series of resorcinol-based N-benzyl benzamide derivatives as potent Hsp90 inhibitors.
    Park SY; Oh YJ; Lho Y; Jeong JH; Liu KH; Song J; Kim SH; Ha E; Seo YH
    Eur J Med Chem; 2018 Jan; 143():390-401. PubMed ID: 29202402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of novel HSP90α/β isoform selective inhibitors using structure-based drug design. demonstration of potential utility in treating CNS disorders such as Huntington's disease.
    Ernst JT; Neubert T; Liu M; Sperry S; Zuccola H; Turnbull A; Fleck B; Kargo W; Woody L; Chiang P; Tran D; Chen W; Snyder P; Alcacio T; Nezami A; Reynolds J; Alvi K; Goulet L; Stamos D
    J Med Chem; 2014 Apr; 57(8):3382-400. PubMed ID: 24673104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRAP1: a viable therapeutic target for future cancer treatments?
    Lettini G; Maddalena F; Sisinni L; Condelli V; Matassa DS; Costi MP; Simoni D; Esposito F; Landriscina M
    Expert Opin Ther Targets; 2017 Aug; 21(8):805-815. PubMed ID: 28664757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential expression of heat shock protein 90 isoforms in small cell lung cancer.
    Lee JH; Kang KW; Kim JE; Hwang SW; Park JH; Kim SH; Ji JH; Kim TG; Nam HY; Roh MS; Lee EH; Park MI; Kim MS; Lee HW
    Int J Clin Exp Pathol; 2015; 8(8):9487-93. PubMed ID: 26464709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency.
    Murray CW; Carr MG; Callaghan O; Chessari G; Congreve M; Cowan S; Coyle JE; Downham R; Figueroa E; Frederickson M; Graham B; McMenamin R; O'Brien MA; Patel S; Phillips TR; Williams G; Woodhead AJ; Woolford AJ
    J Med Chem; 2010 Aug; 53(16):5942-55. PubMed ID: 20718493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transformation of the Non-Selective Aminocyclohexanol-Based Hsp90 Inhibitor into a Grp94-Seletive Scaffold.
    Mishra SJ; Ghosh S; Stothert AR; Dickey CA; Blagg BS
    ACS Chem Biol; 2017 Jan; 12(1):244-253. PubMed ID: 27959508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94.
    Patel HJ; Patel PD; Ochiana SO; Yan P; Sun W; Patel MR; Shah SK; Tramentozzi E; Brooks J; Bolaender A; Shrestha L; Stephani R; Finotti P; Leifer C; Li Z; Gewirth DT; Taldone T; Chiosis G
    J Med Chem; 2015 May; 58(9):3922-43. PubMed ID: 25901531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.